EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Angiogenesis in Glioblastoma—Treatment Approaches

Agnieszka Nowacka iD, Maciej Śniegocki, Wojciech Smuczyński, Dominika Bożiłow iD, Ewa Ziółkowska iD

Cells · 11.03.2025 · 14 (6) · 407

DOI: 10.3390/cells14060407 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 11.03.2025. Verfasst von Agnieszka Nowacka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, Polan…. Hauptthemen laut MEDLINE: Glioblastoma, Neovascularization, Pathologic, Angiogenesis Inhibitors, Brain Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma, the most common primary malignant brain tumor in adults, carries a poor prognosis, with a median survival of just 15 months, significantly impacting patients’ quality of life. The aggressive growth of these highly vascularized tumors relies heavily on angiogenesis, driven primarily by vascular endothelial growth factor-A. Therefore, VEGF signaling pathway has become a prime therapeutic target in GBM treatment over the past decade. While anti-angiogenic treatment showed promise, agents like bevacizumab have ultimately failed to improve overall survival. This highlights the presence of compensatory angiogenic mechanisms that bypass VEGF inhibition, necessitating further investigation into resistance mechanisms and the development of more effective therapeutic strategies. This review examined the current landscape of anti-angiogenic agents for GBM, analyzed the mechanisms driving resistance to these therapies, and explored potential strategies for enhancing their effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNeovascularization, PathologicAngiogenesis InhibitorsBrain NeoplasmsHumansVascular Endothelial Growth Factor AAnimalsSignal TransductionAngiogenesis

Stichwörter der Autor:innen

GBMVEGFangiogenesisanti-angiogenic therapybevacizumabglioblastomaresistancetumor microenvironment

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Neurosurgery, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, Poland.
  • Department of Physiotherapy, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Techników 3, 85-801 Bydgoszcz, Poland.
  • Anaesthesiology and Intensive Care Clinical Ward, The 10th Military Research Hospital and Polyclinic, ul. Powstańców Warszawy 5, 85-681 Bydgoszcz, Poland.
  • Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.

ORCID-Profile: Agnieszka Nowacka, Dominika Bożiłow, Ewa Ziółkowska

Zitieren

APA

Nowacka, A., Śniegocki, M., Smuczyński, W., Bożiłow, D., & Ziółkowska, E. (2025). Angiogenesis in Glioblastoma—Treatment Approaches. Cells, 14(6), 407. https://doi.org/10.3390/cells14060407

Vancouver

Nowacka A, Śniegocki M, Smuczyński W, Bożiłow D, Ziółkowska E. Angiogenesis in Glioblastoma—Treatment Approaches. Cells. 2025;14(6):407. doi:10.3390/cells14060407

BibTeX
@article{Nowacka2025,
  author = {Nowacka, Agnieszka and Śniegocki, Maciej and Smuczyński, Wojciech and Bożiłow, Dominika and Ziółkowska, Ewa},
  title = {Angiogenesis in Glioblastoma—Treatment Approaches},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {6},
  pages = {407},
  doi = {10.3390/cells14060407}
}
Kostenlos starten →